智慧睡眠醫學™（Smart Sleep Medicine™）的先驅 ProSomnus Sleep Technologies（以下簡稱「ProSomnus」），以及睡眠醫學領域首屈一指的數位健康與遠距監測平台 MonitAir, LLC（以下簡稱「MonitAir」），宣布展開合作，旨在為阻塞性睡眠呼吸中止症（OSA）患者提供連網、縱向追蹤及個人化的照護。透過此次合作，開立 ProSomnus RPMO₂ 處方的醫療服務提供者 […]
Author: SleepWorld Magazine
Jazz 於 SLEEP 2026 會議上發表大量數據，揭示 Xywav 對發作性睡病及特發性嗜睡症患者預後的實際影響
Jazz Pharmaceuticals plc delivered 11 late-breaking presentations at SLEEP 2026, including notable new research showcasing the comprehensive treatment outcomes of Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution in patients with narcolepsy and idiopathic hypersomnia (IH). These late-breaking presentations advance scientific understanding of individualized dosing regimens and the broader cardiometabolic […]
「Syn-Sleep」研究：檢測快速眼動睡眠行為障礙患者體內的皮膚磷酸化α-突觸核蛋白
On 星期三 morning, CND Life Sciences presented exciting new data at SLEEP 2026 from the NIH-sponsored Syn-Sleep Study, indicating that its Syn-One Test detected phosphorylated alpha-synuclein (P-SYN) in 75% of patients with idiopathic REM sleep behavior disorder (RBD). SleepWorld had a chance to sit down with CND Chief Medical Officer and […]
最新研究顯示，Inspire 療法有助於減輕缺氧負擔
Inspire Medical Systems, Inc. 參加了於 6 月 14 日至 17 日在馬里蘭州巴爾的摩舉行的 SLEEP 2026——即「專業睡眠學會聯合會」（APSS）第 40 屆年會。SLEEP 是睡眠醫學與研究領域的首要全球論壇，由美國睡眠醫學學會（AASM）與睡眠研究 […] 共同主辦。
最新研究：武田藥業的 Oveporexton 可改善第一型發作性睡病患者的日常功能、認知能力及夜間睡眠品質
New data presented by Takeda at SLEEP 2026 this week continues to build the case for oveporexton (TAK-861) as a potential disease-modifying treatment for narcolepsy type 1 (NT1). Oveporexton is designed to address the root cause of the disease, targeting the underlying orexin deficiency responsible for NT1. Results from two pivotal […]
Nyxoah Announces Pricing of $95 Million Underwritten Public Offering
Nyxoah announced the pricing of an underwritten public offering in the United States, which includes shares sold in a private offering to certain qualified or institutional investors outside the United States, including within the European Union, of 55,232,558 of its ordinary shares at an offering price of $1.72 (EUR 1.48) […]
Huxley Medical Expands SANSA Diagnostic Platform with Point-of-Care Enrollment and Additional Cardiovascular Risk Marker
Huxley Medical, a commercial-stage medical technology company expanding access to sleep apnea testing across health systems, cardiology, and primary care, today introduced two additions to its SANSA® platform: SANSA GO™, a point-of-care enrollment model that enables clinics to dispense SANSA at patient visits, and hypoxic burden, an additional measure of […]
Wesper 將於 SLEEP 2026 大會上推出首個多層級睡眠診斷生態系統，致力於提供個人化睡眠照護
Wesper unveiled its multi-tier sleep diagnostic ecosystem at SLEEP 2026, the annual meeting of the Associated Professional Sleep Societies. The ecosystem brings two purpose-built diagnostic pathways, Wesper Lab and Wesper Lite, onto one platform, one patient record, and one interpretation pipeline, so physicians can match the right test to the right […]
Alkermes 於 SLEEP 2026 會議上發表 Alixorexton 與 LUMRYZ 的研究數據，彰顯其睡眠醫學研究的廣度
Alkermes plc announced plans to present new data from its industry-leading portfolio of sleep medicine research at SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS), taking place 六月 14-17, 2026 in Baltimore, MD. The company will present 26 abstracts, including posters featuring LUMRYZ® (sodium oxybate) extended-release oral […]
Jazz Pharmaceuticals 將於 SLEEP 2026 會議上發表數據，重點介紹 Xywav 對發作性睡病及特發性嗜睡症的療效
Jazz Pharmaceuticals announced that the company will present 21 abstracts, including 11 late-breaking abstracts, at SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS), taking place 六月 14-17, 2026, in Baltimore. The robust breadth of data reflects Jazz’s continued focus on advancing treatment for rare and difficult-to-treat sleep […]
